Last 12 months
Inside the activity.
5 purchase rows · 5 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 3 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 1 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2023 Filed Aug 16, 2023 20:31 UTC |
Binstein RichardEVP Gen'l Counsel & Secretary
|
SaleCommon Stock | 1,000 | $106.60 | $106,600.00 |
DisclosureSEC source: 0001209191-23-046026 · doc4.xml · nonDerivative · entry 1 Binstein Richard · CIK 0001919840 · EVP Gen'l Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,906 F1 · balance_after: Includes 7,970 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 968 shares on October 1, 2023 and on January 1, 2024; 733 shares on each of April 1, 2024, July 1,2024, and October 1, 2024; 734 shares on January 1, 2025; 539 shares on each of April 1, 2025, July 1, 2025 and October 1, 2025; 542 shares on January 1, 2026, 234 shares on April 1, 2026, July 1, 2026 and October 1, 2026 and 240 shares on January 1, 2027 if he is an employee of the Company on those dates. Read SEC document |
| August 14, 2023 Filed Aug 14, 2023 21:07 UTC |
KUNTZ EDWARD LDirector
|
SaleCommon Stock | 1,000 | $107.60 | $107,600.00 |
DisclosureSEC source: 0001209191-23-045675 · doc4.xml · nonDerivative · entry 2 KUNTZ EDWARD L · CIK 0001182168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,280 F1 · balance_after: Includes 1,200 shares of common stock that were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on October 1, 2023, January 1, 2024 and April 1, 2024, if he is a director of the Company on those dates. Read SEC document |
| August 11, 2023 Filed Aug 14, 2023 21:07 UTC |
KUNTZ EDWARD LDirector
|
SaleCommon Stock | 1,000 | $109.95 | $109,950.00 |
DisclosureSEC source: 0001209191-23-045675 · doc4.xml · nonDerivative · entry 1 KUNTZ EDWARD L · CIK 0001182168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,280 F1 · balance_after: Includes 1,200 shares of common stock that were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on October 1, 2023, January 1, 2024 and April 1, 2024, if he is a director of the Company on those dates. Read SEC document |
| August 11, 2023 Filed Aug 14, 2023 20:59 UTC | SaleCommon Stock | 4,114 | $109.99 | $452,498.86 |
DisclosureSEC source: 0001209191-23-045664 · doc4.xml · nonDerivative · entry 2 REEVE GRAHAM D. · CIK 0001519948 · COO 10b5-1 filing: No plan indicated Ownership: Indirect · Reeve Trust Disclosed balance after: 7,577 F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.27 to $111.14, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
|
| May 16, 2023 Filed May 18, 2023 21:02 UTC |
Trier ClaytonDirector
|
GrantCommon Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030689 · doc4.xml · nonDerivative · entry 1 Trier Clayton · CIK 0001319561 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,070 F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2023, October 1, 2023, January 1, 2024 and April 1, 2023, if he is a director of the Company on those dates. F2 · balance_after: Includes the 1,600 shares of restricted stock granted under the Company equity plans mentioned in Note 1. Read SEC document |
| May 16, 2023 Filed May 18, 2023 21:00 UTC |
Swanson Regg E.Director
|
GrantCommon Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030680 · doc4.xml · nonDerivative · entry 1 Swanson Regg E. · CIK 0001412473 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,880 F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2023, October 1, 2023, January 1, 2024 and April 1, 2023, if he is a director of the Company on those dates. F2 · balance_after: Includes the 1,600 shares of restricted stock granted under the Company equity plans mentioned in Note 1. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:57 UTC |
KUNTZ EDWARD LDirector
|
GrantCommon Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030669 · doc4.xml · nonDerivative · entry 1 KUNTZ EDWARD L · CIK 0001182168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,280 F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2023, October 1, 2023, January 1, 2024 and April 1, 2023, if he is a director of the Company on those dates. F2 · balance_after: Includes the 1,600 shares of restricted stock granted under the Company equity plans mentioned in Note 1. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:30 UTC |
Motsenbocker AnneDirector
|
GrantCommon Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030640 · doc4.xml · nonDerivative · entry 1 Motsenbocker Anne · CIK 0001904253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,200 F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2023, October 1, 2023, January 1, 2024 and April 1, 2023, if she is a director of the Company on those dates. F2 · balance_after: Includes the 1,600 shares of restricted stock granted under the Company equity plans mentioned in Note 1. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:27 UTC |
Harris Bernard A JrDirector
|
GrantCommon Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030637 · doc4.xml · nonDerivative · entry 1 Harris Bernard A Jr · CIK 0001337906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,302 F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2023, October 1, 2023, January 1, 2024 and April 1, 2023, if he is a director of the Company on those dates. F2 · balance_after: Includes the 1,600 shares of restricted stock granted under the Company equity plans mentioned in Note 1. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:15 UTC |
Gilmartin Kathleen ADirector
|
GrantCommon Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030619 · doc4.xml · nonDerivative · entry 1 Gilmartin Kathleen A · CIK 0001741732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,480 F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2023, October 1, 2023, January 1, 2024 and April 1, 2023, if she is a director of the Company on those dates. F2 · balance_after: Includes the 1,600 shares of restricted stock granted under the Company equity plans mentioned in Note 1. Read SEC document |
| May 16, 2023 Filed May 26, 2023 20:04 UTC |
HAM NANCYDirector
|
GrantCommon Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032493 · doc4.xml · nonDerivative · entry 1 HAM NANCY · CIK 0001124500 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,600 F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2023, October 1, 2023, January 1, 2024 and April 1, 2023, if she is a director of the Company on those dates. F2 · balance_after: Includes the 1,600 shares of restricted stock granted under the Company equity plans mentioned in Note 1. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 20:17 UTC |
Harris Bernard A JrDirector
|
SaleCommon Stock | 5,000 | $92.50 | $462,500.00 |
DisclosureSEC source: 0001209191-23-019283 · doc4.xml · nonDerivative · entry 1 Harris Bernard A Jr · CIK 0001337906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,702 F1 · balance_after: Includes 400 shares of common stock granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares on April 1, 2023, if he is a director of the Company on those dates. Read SEC document |
| March 13, 2023 Filed Mar 16, 2023 20:13 UTC |
HENDRICKSON CAREY PChief Financial Officer
|
SaleCommon Stock | 471 | $95.80 | $45,121.80 |
DisclosureSEC source: 0001209191-23-019266 · doc4.xml · nonDerivative · entry 1 HENDRICKSON CAREY P · CIK 0001482760 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,886 F1 · balance_after: Includes 10,996 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 932 shares on each of April 1, 2023 July 1, 2023, October 1, 2023, January 1, 2024, April 1, 2024 and July 1, 2024; 940 shares on October 1, 2024; 702 shares on each of January 1, 2025, April 1, 2025, July 1, 2025 and October 1, 2025; 714 shares on January 1, 2026; 234 shares on each of April 1, 2026, July 1, 2026 and October 1, 2026; and the final 240 shares on January 1, 2027, if he is an employee of the Company on those dates. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:37 UTC |
Williams Eric JosephCo-Chief Operations Officer
|
SaleCommon Stock | 650 | $101.70 | $66,105.00 |
DisclosureSEC source: 0001209191-23-016291 · doc4.xml · nonDerivative · entry 2 Williams Eric Joseph · CIK 0001871391 · Co-Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,714 F1 · balance_after: Includes 9,036 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 624 shares on each of April 1, 2023, July 1, 2023, October 1, 2023, January 1, 2024, April 1, 2024, July 1, 2024, October 1, 2024, January 1, 2025 and April 1, 2025; 908 shares on July 1, 2025; 624 shares on October 1, 2025; 632 shares on January 1, 2026; and 312 shares on April 1, 2026, July 1, 2026 and October 1, 2026 and the final 320 shares on January 1, 2027, if he is an employee of the Company on those dates. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:37 UTC |
Williams Eric JosephCo-Chief Operations Officer
|
SaleCommon Stock | 500 | $101.60 | $50,800.00 |
DisclosureSEC source: 0001209191-23-016291 · doc4.xml · nonDerivative · entry 1 Williams Eric Joseph · CIK 0001871391 · Co-Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,364 F1 · balance_after: Includes 9,036 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 624 shares on each of April 1, 2023, July 1, 2023, October 1, 2023, January 1, 2024, April 1, 2024, July 1, 2024, October 1, 2024, January 1, 2025 and April 1, 2025; 908 shares on July 1, 2025; 624 shares on October 1, 2025; 632 shares on January 1, 2026; and 312 shares on April 1, 2026, July 1, 2026 and October 1, 2026 and the final 320 shares on January 1, 2027, if he is an employee of the Company on those dates. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:24 UTC |
Trier ClaytonDirector
|
SaleCommon Stock | 370 | $102.69 | $37,995.30 |
DisclosureSEC source: 0001209191-23-016275 · doc4.xml · nonDerivative · entry 1 Trier Clayton · CIK 0001319561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,470 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $102.60 to $102.77, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 400 shares of common stock granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares on April 1, 2023, if he is a director of the Company on that dates. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 15:20 UTC |
Binstein RichardEVP Gen'l Counsel & Secretary
|
SaleCommon Stock | 911 | $100.78 | $91,810.58 |
DisclosureSEC source: 0001209191-23-015149 · doc4.xml · nonDerivative · entry 1 Binstein Richard · CIK 0001919840 · EVP Gen'l Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,906 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.71 to $100.90, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 9,906 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 968 shares on each of April 1, 2023, July 1, 2023, October 1, 2023, and on January 1, 2024; 733 shares on each of April 1, 2024, July 1,2024, and October 1, 2024; 734 shares on January 1, 2025; 539 shares on each of April 1, 2025, July 1, 2025 and October 1, 2025; 542 shares on January 1, 2026 and 234 shares on April 1, 2026, if he is an employee of the Company on those dates. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:11 UTC | SaleCommon Stock | 1,912 | $100.95 | $193,016.40 |
DisclosureSEC source: 0001209191-23-016252 · doc4.xml · nonDerivative · entry 2 REEVE GRAHAM D. · CIK 0001519948 · COO 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 8,243 F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.73 to $101.00, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
|
| February 20, 2023 Filed Feb 23, 2023 22:56 UTC |
Williams Eric JosephCo-Chief Operations Officer
|
GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012323 · doc4.xml · nonDerivative · entry 1 Williams Eric Joseph · CIK 0001871391 · Co-Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,864 F1 · shares: The 5,000 shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 quarterly installments with 312 shares vesting on the first day of each of the succeeding fifteen quarters beginning on April 1, 2023, and with the final 320 shares vesting on January 1, 2027, if he is employed by the Company on those dates. F2 · balance_after: Includes 9,036 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 624 shares on each of April 1, 2023, July 1, 2023, October 1, 2023, January 1, 2024, April 1, 2024, July 1, 2024, October 1, 2024, January 1, 2025 and April 1, 2025; 908 shares on July 1, 2025; 624 shares on October 1, 2025; 632 shares on January 1, 2026; and 312 shares on April 1, 2026, July 1, 2026 and October 1, 2026 and the final 320 shares on January 1, 2027, if he is an employee of the Company on those dates. Read SEC document |
| February 20, 2023 Filed Feb 23, 2023 21:40 UTC |
READING CHRISTOPHER JDirector · Chief Executive Officer
|
GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012213 · doc4.xml · nonDerivative · entry 1 READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,638 F1 · shares: The 10,000 shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 equal quarterly installments with the first 625 shares vesting on April 1, 2023 and with the final 625 shares vesting on January 1, 2027, if he is employed by the Company on those dates. F2 · balance_after: Includes 34,204 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 3,473 shares on each of April 1, 2023, July 1, 2023 and October 1, 2023; 3,485 shares on January 1, 2024; 2,575 shares on each of April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025; 1,875 shares on each of April 1, 2025, July 1, 2025, October 1, 2025; and January 1, 2026; and 625 shares on each of April 1, 2026, July 1, 2026, October 1, 2026 and January 1, 2027, if he is an employee of the Company on those dates. Read SEC document |
| February 20, 2023 Filed Feb 23, 2023 21:37 UTC | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012208 · doc4.xml · nonDerivative · entry 2 REEVE GRAHAM D. · CIK 0001519948 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,062 F1 · shares: The 5,000 shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 quarterly installments with 312 shares vesting on the first day of each of the succeeding fifteen quarters beginning on April 1, 2023, and with the final 320 shares vesting on January 1, 2027, if he is employed by the Company on those dates. F2 · balance_after: Includes 17,062 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,724 shares on each of April 1, 2023, July 1, 2023, October 1, 2023; 1,730 shares on January 1, 2024; 1,286 shares on each of April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025; 936 shares on each of April 1, 2025 July 1, 2025 and October 1, 2025; 952 shares on January 1, 2026; and 312 shares on each of April 1, 2026, July 1, 2026 and October 1, 2026; and the final 320 shares on January 1, 2027, if he is an employee of the Company on those dates. Read SEC document |
|
| February 20, 2023 Filed Feb 23, 2023 21:35 UTC |
HENDRICKSON CAREY PChief Financial Officer
|
GrantCOMMON STOCK | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012205 · doc4.xml · nonDerivative · entry 1 HENDRICKSON CAREY P · CIK 0001482760 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,357 F1 · shares: The 3,750 shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 quarterly installments with 234 shares vesting on the first day of each of the succeeding fifteen quarters beginning on April 1, 2023, and with the final 240 shares vesting on January 1, 2027, if he is employed by the Company on those dates. F2 · balance_after: Includes 10,996 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 932 shares on each of April 1, 2023 July 1, 2023, October 1, 2023, January 1, 2024, April 1, 2024 and July 1, 2024; 940 shares on October 1, 2024; 702 shares on each of January 1, 2025, April 1, 2025, July 1, 2025 and October 1, 2025; 714 shares on January 1, 2026; 234 shares on each of April 1, 2026, July 1, 2026 and October 1, 2026; and the final 240 shares on January 1, 2027, if he is an employee of the Company on those dates. Read SEC document |
| February 20, 2023 Filed Feb 23, 2023 21:31 UTC |
Binstein RichardEVP Gen'l Counsel & Secretary
|
GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012195 · doc4.xml · nonDerivative · entry 1 Binstein Richard · CIK 0001919840 · EVP Gen'l Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,817 F1 · shares: The 3,750 shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 quarterly installments with 234 shares vesting on the first day of each of the succeeding fifteen quarters beginning on April 1, 2023, and with the final 240 shares vesting on January 1, 2027, if he is employed by the Company on those dates. F2 · balance_after: Includes 9,906 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 968 shares on each of April 1, 2023, July 1, 2023, October 1, 2023, and January 1, 2024; 733 shares on each of April 1, 2024, July 1, 2024, and October 1, 2024; 734 shares on January 1, 2025; 539 shares on each of April 1, 2025, July 1, 2025 and October 1, 2025; 542 shares on January 1, 2026; and 234 shares on each of April 1, 2026, July 1, 2026 and October 1, 2026; with the final 240 shares on January 1, 2027, if he is an employee of the Company on those dates. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 17:21 UTC |
Chapman Harry SDirector
|
SaleCommon Stock | 4,160 | $84.09 | $349,814.40 |
DisclosureSEC source: 0001209191-22-061804 · doc4.xml · nonDerivative · entry 1 Chapman Harry S · CIK 0001500817 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,740 F1 · price: The price reported is a weighted average price $84.09 The shares were sold in multiple transactions at prices ranging from $84.00 to $84.90 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 800 shares of common stock which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 400 shares on January 1, 2023, and 400 shares on April 1, 2023, if he is a director of the Company on that date. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 15:54 UTC |
Chapman Harry SDirector
|
SaleCommon Stock | 43 | $86.06 | $3,700.58 |
DisclosureSEC source: 0001209191-22-061785 · doc4.xml · nonDerivative · entry 2 Chapman Harry S · CIK 0001500817 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,900 F1 · balance_after: Includes 800 shares of common stock which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 400 shares on January 1, 2023, and 400 shares on April 1, 2023, if he is a director of the Company on that date. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 15:54 UTC |
Chapman Harry SDirector
|
SaleCommon Stock | 2,957 | $86.00 | $254,302.00 |
DisclosureSEC source: 0001209191-22-061785 · doc4.xml · nonDerivative · entry 1 Chapman Harry S · CIK 0001500817 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,943 F1 · balance_after: Includes 800 shares of common stock which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 400 shares on January 1, 2023, and 400 shares on April 1, 2023, if he is a director of the Company on that date. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 17:29 UTC |
HENDRICKSON CAREY PChief Financial Officer
|
SaleCommon Stock | 550 | $87.85 | $48,317.50 |
DisclosureSEC source: 0001209191-22-060876 · doc4.xml · nonDerivative · entry 1 HENDRICKSON CAREY P · CIK 0001482760 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,607 F1 · price: The price reported is a weighted average price $87.85. The shares were sold in multiple transactions at prices ranging from $87.76 to $87.92 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Included are 7,944 shares of common stock which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in quarterly installments as follows: 698 shares on each of January 1, April 1, July 1, October 1, 2023 and January 1, April 1, and July 1, 2024; 706 shares on October 1, 2024; 468 shares on each of January 1, April 1, July 1 and October 1, 2025; and 480 shares on January 1, 2026. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 19:56 UTC |
READING CHRISTOPHER JDirector · Chief Executive Officer
|
SaleCommon Stock | 5,000 | $90.00 | $450,000.00 |
DisclosureSEC source: 0001209191-22-060139 · doc4.xml · nonDerivative · entry 1 READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,638 F1 · balance_after: Includes 28,333 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 4,129 shares on January 1, 2023; 2,848 shares on each of April 1, July 1 and October 1, 2023; 2,860 shares on January 1, 2024; 1,950 shares on each of April 1, July 1 and October 1, 2024, and on January 1, 2025; and 1,250 shares on each of April 1, July 1 and October 1, 2025, and on January 1, 2026, if he is an employee of the Company on those dates. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 20:29 UTC |
Chapman Harry SDirector
|
SaleCommon Stock | 8,600 | $90.82 | $781,052.00 |
DisclosureSEC source: 0001209191-22-059619 · doc4.xml · nonDerivative · entry 1 Chapman Harry S · CIK 0001500817 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,900 F1 · price: The price reported is a weighted average price $90.82. The shares were sold in multiple transactions at prices ranging from $90.70 to $91.03 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes the 800 shares of common stock that were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of January 1, 2023 and April 1, 2023, if he is a director of the Company on those dates Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 20:28 UTC |
READING CHRISTOPHER JDirector · Chief Executive Officer
|
SaleCommon stock | 10,000 | $90.01 | $900,100.00 |
DisclosureSEC source: 0001209191-22-059618 · doc4.xml · nonDerivative · entry 1 READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,638 F1 · price: The price reported is a weighted average price $90.01. The shares were sold in multiple transactions at prices ranging from $90.00 to $90.44 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 28,333 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 4,129 shares on January 1, 2023; 2,848 shares on each of April 1, July 1 and October 1, 2023; 2,860 shares on January 1, 2024; 1,950 shares on each of April 1, July 1 and October 1, 2024, and on January 1, 2025; and 1,250 shares on each of April 1, July 1 and October 1, 2025, and on January 1, 2026, if he is an employee of the Company on those dates. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 19:05 UTC |
Trier ClaytonDirector
|
SaleCommon Stock | 400 | $89.57 | $35,828.00 |
DisclosureSEC source: 0001209191-22-059591 · doc4.xml · nonDerivative · entry 3 Trier Clayton · CIK 0001319561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,840 F4 · price: The price reported is a weighted average price $89.57. The shares were sold in multiple transactions at prices ranging from $89.50 to $89.60 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: 800 of these shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares on January 1, 2023 and April 1, 2023, if he is a director of the Company on those dates. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 19:05 UTC |
Trier ClaytonDirector
|
SaleCommon Stock | 1,540 | $88.09 | $135,658.60 |
DisclosureSEC source: 0001209191-22-059591 · doc4.xml · nonDerivative · entry 2 Trier Clayton · CIK 0001319561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,240 F3 · price: The price reported is a weighted average price $88.09. The shares were sold in multiple transactions at prices ranging from $87.80 to $88.41 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: 800 of these shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares on January 1, 2023 and April 1, 2023, if he is a director of the Company on those dates. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 19:05 UTC |
Trier ClaytonDirector
|
SaleCommon Stock | 800 | $88.68 | $70,944.00 |
DisclosureSEC source: 0001209191-22-059591 · doc4.xml · nonDerivative · entry 1 Trier Clayton · CIK 0001319561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,780 F1 · price: The price reported is a weighted average price $88.68. The shares were sold in multiple transactions at prices ranging from $88.45 to $88.95 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: 800 of these shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares on January 1, 2023 and April 1, 2023, if he is a director of the Company on those dates. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 19:01 UTC |
BROOKNER MARK JDirector
|
SaleCommon Stock | 1,600 | $84.00 | $134,400.00 |
DisclosureSEC source: 0001209191-22-057260 · doc4.xml · nonDerivative · entry 1 BROOKNER MARK J · CIK 0000938954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,830 F1 · balance_after: Includes 800 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of January 1, 2023 and April 1, 2023, if he is a director of the Company on those dates. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:54 UTC |
Binstein RichardEVP Gen'l Counsel & Secretary
|
SaleCommon Stock | 904 | $85.86 | $77,617.44 |
DisclosureSEC source: 0001209191-22-056119 · doc4.xml · nonDerivative · entry 1 Binstein Richard · CIK 0001919840 · EVP Gen'l Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,067 F1 · price: The price reported is a weighted average price $85.86. The shares were purchased in multiple transactions at prices ranging from $85.83 to $85.88 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 7,067 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 911 shares on January 1, 2023; 734 shares on each of April 1, July 1 and October 1, 2023, and on January 1, 2024; 499 shares on each of April 1, July 1 and October 1, 2024; 500 shares on January 1, 2025; 305 shares on each of April 1, July 1 and October 1, 2025; and 308 shares on January 1, 2026, if he is an employee of the Company on those dates. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:51 UTC |
Williams Eric JosephCo-Chief Operations Officer
|
SaleCommon Stock | 590 | $86.04 | $50,763.60 |
DisclosureSEC source: 0001209191-22-056117 · doc4.xml · nonDerivative · entry 1 Williams Eric Joseph · CIK 0001871391 · Co-Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,864 F1 · balance_after: Includes 7,128 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 590 shares on each of January 1, April 1, July 1 and October 1, 2023, and on each of January 1, April 1, July 1 and October 1, 2024, and on each of January 1 and April 1, 2025; 596 shares on July 1, 2025; 312 shares on October 1, 2025; and 320 shares on January 1, 2026, if he is an employee of the Company on those dates. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:47 UTC | SaleCommon Stock | 1,909 | $84.79 | $161,864.11 |
DisclosureSEC source: 0001209191-22-056112 · doc4.xml · nonDerivative · entry 1 REEVE GRAHAM D. · CIK 0001519948 · COO 10b5-1 filing: Not disclosed Ownership: Indirect · Reeve Trust Disclosed balance after: 8,083 F1 · price: The price reported is a weighted average price $84.79 The shares were purchased in multiple transactions at prices ranging from $84.55 to $85.00 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
|
| September 12, 2022 Filed Sep 13, 2022 17:52 UTC |
HENDRICKSON CAREY PChief Financial Officer
|
GiftCommon Stock | 31 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-049654 · doc4.xml · nonDerivative · entry 1 HENDRICKSON CAREY P · CIK 0001482760 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,157 F1 · balance_after: Includes 8,642 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 698 shares on each of October 1, 2022, January 1, 2023, April 1, 2023, July 1, 2023, October 1, 2023, January 1, 2024, April 1, 2024 and July 1, 2024, 706 shares lapse on October 1, 2024 and 468 shares lapse on each of January 1, April 1, July 1 and October 1, 2025 with the final 480 shares to lapse on January 1, 2026. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 14:51 UTC |
Chapman Harry SDirector
|
SaleCommon Stock | 3,000 | $80.50 | $241,500.00 |
DisclosureSEC source: 0001209191-22-049854 · doc4.xml · nonDerivative · entry 2 Chapman Harry S · CIK 0001500817 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 F1 · balance_after: Includes the 1,200 shares of common stock that were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of October 1, 2022, January 1, 2023 and April 1, 2023, if he is a director of the Company on those dates Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 14:51 UTC |
Chapman Harry SDirector
|
SaleCommon Stock | 2,000 | $80.50 | $161,000.00 |
DisclosureSEC source: 0001209191-22-049854 · doc4.xml · nonDerivative · entry 1 Chapman Harry S · CIK 0001500817 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 F1 · balance_after: Includes the 1,200 shares of common stock that were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of October 1, 2022, January 1, 2023 and April 1, 2023, if he is a director of the Company on those dates Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 15:22 UTC |
Swanson Regg E.Director
|
PurchaseCommon Stock | 1,000 | $77.65 | $77,650.00 |
DisclosureSEC source: 0001209191-22-048963 · doc4.xml · nonDerivative · entry 2 Swanson Regg E. · CIK 0001412473 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 7,596 F2 · ownership.nature: Regg E Swanson Revocable Trust is the owner, and Regg E Swanson is Beneficiary and Trustee Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 18:50 UTC |
Chapman Harry SDirector
|
SaleCommon Stock | 3,000 | $76.73 | $230,190.00 |
DisclosureSEC source: 0001209191-22-049131 · doc4.xml · nonDerivative · entry 2 Chapman Harry S · CIK 0001500817 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 F1 · balance_after: Includes the 1,200 shares of common stock that were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of October 1, 2022, January 1, 2023 and April 1, 2023, if he is a director of the Company on those dates. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 18:50 UTC |
Chapman Harry SDirector
|
SaleCommon Stock | 2,000 | $76.70 | $153,400.00 |
DisclosureSEC source: 0001209191-22-049131 · doc4.xml · nonDerivative · entry 1 Chapman Harry S · CIK 0001500817 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 F1 · balance_after: Includes the 1,200 shares of common stock that were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of October 1, 2022, January 1, 2023 and April 1, 2023, if he is a director of the Company on those dates. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 15:09 UTC |
Gilmartin Kathleen ADirector
|
PurchaseCommon Stock | 1,000 | $81.71 | $81,710.00 |
DisclosureSEC source: 0001209191-22-047678 · doc4.xml · nonDerivative · entry 1 Gilmartin Kathleen A · CIK 0001741732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,880 F1 · price: The price reported is a weighted average price $81.71. The shares were purchased in multiple transactions at prices ranging from $81.45 to $81.79 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 1,200 shares of common stock which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of October 1, 2022, January 1, 2023, and April 1, 2023, if she is a director of the Company on those dates. Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 14:52 UTC |
Binstein RichardEVP Gen'l Counsel & Secretary
|
SaleCommon Stock | 1,808 | $90.43 | $163,497.44 |
DisclosureSEC source: 0001209191-22-045752 · doc4.xml · nonDerivative · entry 1 Binstein Richard · CIK 0001919840 · EVP Gen'l Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,971 F1 · price: The shares were sold in multiple transactions at prices ranging from $90.00 to $90.57 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 7,971 shares of common stock which was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 904 shares on October 1, 2022; 911 shares on January 1, 2023; 734 shares on each of April 1, July 1 and October 1, 2023 and January 1, 2024; 499 shares on each of April 1, July 1 and October 1, 2024; 500 shares on January 1, 2025; 305 shares on each of April 1, July 1 and October 1, 2025; and the final 308 shares on January 1, 2026, if he is employed by the Company on those dates. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 16:35 UTC |
Motsenbocker AnneDirector
|
PurchaseCommon Stock | 500 | $92.29 | $46,145.00 |
DisclosureSEC source: 0001209191-22-045143 · doc4.xml · nonDerivative · entry 1 Motsenbocker Anne · CIK 0001904253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 F1 · balance_after: Includes 1,200 shares of common stock which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares on October 1, 2022, January 1, 2023, and April 1, 2023, if she is still a director of the Company on those dates. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 15:55 UTC |
Gilmartin Kathleen ADirector
|
PurchaseCommon Stock | 600 | $92.26 | $55,356.00 |
DisclosureSEC source: 0001209191-22-044937 · doc4.xml · nonDerivative · entry 1 Gilmartin Kathleen A · CIK 0001741732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,880 F1 · price: The price reported is a weighted average price $92.26. The shares were purchased in multiple transactions at prices ranging from $92.25 to $92.32 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 1,200 shares of common stock which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of October 1, 2022, January 1, 2023, and April 1, 2023, if she is a director of the Company on those dates. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 16:36 UTC | SaleCommon Stock | 3,818 | $92.24 | $352,172.32 |
DisclosureSEC source: 0001209191-22-045144 · doc4.xml · nonDerivative · entry 1 REEVE GRAHAM D. · CIK 0001519948 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,191 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.12 to $92.50 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 16,191 shares which restrictions lapse as to 2,057 shares on October 1, 2022; 2,072 shares on January 1, 2023; 1,412 shares on each of April 1, July 1, and October 1, 2023; 1,418 shares on January 1, 2024; and 974 shares on each of April 1, July 1, and October 1, 2024; 974 shares on January 1, 2025; and 624 shares on April 1, July 1, October 1, 2025 with the final 640 shares lapsing on January 1, 2026 if he is still employed by the Company on those dates. Read SEC document |
|
| May 16, 2022 Filed May 18, 2022 15:53 UTC |
Swanson Regg E.Director
|
GrantCommon Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-029944 · doc4.xml · nonDerivative · entry 1 Swanson Regg E. · CIK 0001412473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,280 F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2022, October 1, 2022, January 1, 2023 and April 1, 2023, if he is a director of the Company on those dates. F2 · balance_after: Includes the 1,600 shares of restricted stock granted under the Company equity plans mentioned in Note 1. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:26 UTC |
Gilmartin Kathleen ADirector
|
GrantCommon Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-030040 · doc4.xml · nonDerivative · entry 1 Gilmartin Kathleen A · CIK 0001741732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,280 F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares lapsed on each of July 1, 2022, October 1, 2022, January 1, 2023 and April 1, 2023, if she is a director of the Company on those dates. F2 · balance_after: Includes the 1,600 shares of restricted stock granted under the Company equity plans mentioned in Note 1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.